{"success":true,"data":{"pressRelease":{"id":"147832","rtpr_id":"nACSrxHBBa-20260919","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX Deadline Alert: Beta Bionics Investors Are Reminded of The Ongoing Securities Fraud Class Action to Recover Losses and Imminent November 3 Case Deadline ","author":"ACCESSWIRE","published_at":"2026-09-19T10:18:12.807Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 19, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/qg3g) announces that a class action lawsuit has been filed\nagainst Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n* Lead Plaintiff Deadline: November 3, 2026\n* Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n* Largest Alleged Stock Drop: January 8-9, 2026 - 37% Stock Drop\n* Court: U.S. District Court for the Central District of California\n* Action: Contact BFA Law (https://pr.report/qg3i) to discuss your rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v. Beta\nBionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (\"iLet\"), launched in 2023. The iLet is an\ninsulin delivery system for treatment of diabetes types 1 and 2 that purports\nto be fully autonomous, determining 100% of insulin doses without manual\ncarbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted \"the superior clinical\noutcomes of the iLet\" and that healthcare professionals \"are seeing good\nresults from their patients and becoming more comfortable prescribing the\niLet.\"\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet's aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics' Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric-the number of new patients starting iLet treatment, or \"new patient\nstarts\"-had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360, and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"there is no better service provider in the practice area,\" \"the\ninterest of the client is always front and center,\" and \"there isn't a better\nfirm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar Fonti & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-deadline-alert-beta-bionics-investors-are-reminded-of-the-o-1223274)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSrxHBBa-20260919","title":"BBNX Deadline Alert: Beta Bionics Investors Are Reminded of The Ongoing Securities Fraud Class Action to Recover Losses and Imminent November 3 Case Deadline ","author":"ACCESSWIRE","ticker":"BBNX","created":"2026-09-19T10:18:12.807Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 19, 2026 / Leading securities law firm Bleichmar Fonti & Auld LLP\n(https://pr.report/qg3g) announces that a class action lawsuit has been filed\nagainst Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n* Lead Plaintiff Deadline: November 3, 2026\n* Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n* Largest Alleged Stock Drop: January 8-9, 2026 - 37% Stock Drop\n* Court: U.S. District Court for the Central District of California\n* Action: Contact BFA Law (https://pr.report/qg3i) to discuss your rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v. Beta\nBionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (\"iLet\"), launched in 2023. The iLet is an\ninsulin delivery system for treatment of diabetes types 1 and 2 that purports\nto be fully autonomous, determining 100% of insulin doses without manual\ncarbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted \"the superior clinical\noutcomes of the iLet\" and that healthcare professionals \"are seeing good\nresults from their patients and becoming more comfortable prescribing the\niLet.\"\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet's aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics' Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric-the number of new patients starting iLet treatment, or \"new patient\nstarts\"-had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named \"Elite Trial Lawyers\" by the National Law Journal, \"Litigation\nStars\" by Benchmark Litigation, among the top \"500 Leading Plaintiff Financial\nLawyers\" by Lawdragon, \"Titans of the Plaintiffs' Bar\" by Law360, and\n\"SuperLawyers\" by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff's securities litigation law firm, with clients\nnoting: \"there is no better service provider in the practice area,\" \"the\ninterest of the client is always front and center,\" and \"there isn't a better\nfirm in this space.\" One testimonial described the firm as \"nimble and\nentrepreneurial,\" with a \"relentless focus on adding value for clients.\"\n\nBFA's notable successes include a recovery of over $900 million in value from\nTesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\nSOURCE: Bleichmar Fonti & Auld LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-deadline-alert-beta-bionics-investors-are-reminded-of-the-o-1223274)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-19T10:18:12.869273724Z","server_sent_at_ms":1789813092869},"received_at":"2026-09-19T10:18:12.925Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-deadline-alert-beta-bionics-investors-are-reminded-of-the-o-1223274"},"analysis":{"id":"136642","press_release_id":"147832","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":["FDA Form 483 (June 2025) cited more than 18,000 unreported iLet complaints, including life-threatening hypoglycemia from aggressive insulin dosing","FDA 10-page warning letter publicly released February 24, 2026 over failure to report iLet hypoglycemia malfunctions","Securities fraud class action pending under Sections 10(b) and 20(a); lead plaintiff deadline November 3, 2026","Allegations the company failed to investigate or take corrective action on device safety complaints","New patient starts missed analyst estimates by nearly 10%, driving a 37% two-day stock decline in January 2026"],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP, a plaintiff securities firm, issued a deadline alert reminding Beta Bionics investors of the ongoing securities fraud class action and a November 3, 2026 lead plaintiff deadline.\n\nThe complaint alleges Beta Bionics misled investors about iLet safety, citing a June 2025 FDA Form 483 that detailed more than 18,000 unreported user complaints, including life-threatening hypoglycemia tied to the device's insulin dosing algorithm.\n\nBBNX stock fell 37% on January 8-9, 2026 after new patient starts missed analyst estimates by nearly 10%, then dropped another 4.9% in late February after the FDA publicly released a warning letter over unreported iLet malfunctions.\n\nThis is law-firm marketing rather than an issuer disclosure; the case is Holtzman v. Beta Bionics, Inc., No. 26-cv-9999, pending in the U.S. District Court for the Central District of California.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm deadline reminder -- suppress; the underlying FDA warning-letter and device-safety allegations are the substantive risk, not the solicitation."},"keyFigures":{"customDimensions":{"court":"U.S. District Court for the Central District of California","case_caption":"Holtzman v. Beta Bionics, Inc., No. 26-cv-9999","stock_drop_jan_2026":"$11.85 per share decline (from $31.99 on Jan 8, 2026 to $20.14 on Jan 9, 2026)","largest_stock_drop_pct":"37%","lead_plaintiff_deadline":"November 3, 2026","stock_drop_feb_2026_pct":"4.9%","fda_form_483_unreported_complaints":"more than 18,000","new_patient_starts_miss_vs_estimates":"nearly 10%"}},"quotedText":"are seeing good results from their patients and becoming more comfortable prescribing the iLet.","namedEntities":{"people":[{"name":"Adam McCall","role":"attorney/contact at Bleichmar Fonti & Auld LLP"},{"name":"Holtzman","role":"named plaintiff in the class action (case caption)"}],"products":["iLet Bionic Pancreas insulin pump","iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action defendant / issuer (target)"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff securities law firm (release author)"},{"name":"Tesla, Inc.","relationship":"mentioned in law-firm marketing (past recovery)"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned in law-firm marketing (past recovery)"}],"dollarAmounts":[{"amount":"$11.85","context":"per-share stock decline January 8-9, 2026"},{"amount":"$31.99","context":"BBNX closing price January 8, 2026"},{"amount":"$20.14","context":"BBNX closing price January 9, 2026"},{"amount":"$0.66","context":"per-share stock decline February 24-25, 2026"},{"amount":"$13.55","context":"BBNX closing price February 24, 2026"},{"amount":"$12.89","context":"BBNX closing price February 25, 2026"},{"amount":"over $900 million","context":"BFA's past recovery from Tesla, Inc.'s Board of Directors (law-firm marketing)"},{"amount":"$420 million","context":"BFA's past recovery from Teva Pharmaceutical Ind. Ltd. (law-firm marketing)"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Bleichmar Fonti & Auld LLP reminding Beta Bionics investors of the November 3, 2026 lead plaintiff deadline. No certified class, no settlement, and no new issuer disclosure -- the release recaps previously reported stock drops and FDA actions."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":14,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"lawFirm":"Bleichmar Fonti & Auld LLP","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRisk":"FDA warning letter and device-safety allegations are material to BBNX but already public"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP, a plaintiff securities firm, issued a deadline alert reminding Beta Bionics investors of the ongoing securities fraud class action and a November 3, 2026 lead plaintiff deadline.\n\nThe complaint alleges Beta Bionics misled investors about iLet safety, citing a June 2025 FDA Form 483 that detailed more than 18,000 unreported user complaints, including life-threatening hypoglycemia tied to the device's insulin dosing algorithm.\n\nBBNX stock fell 37% on January 8-9, 2026 after new patient starts missed analyst estimates by nearly 10%, then dropped another 4.9% in late February after the FDA publicly released a warning letter over unreported iLet malfunctions.\n\nThis is law-firm marketing rather than an issuer disclosure; the case is Holtzman v. Beta Bionics, Inc., No. 26-cv-9999, pending in the U.S. District Court for the Central District of California.","key_figures":{"customDimensions":{"court":"U.S. District Court for the Central District of California","case_caption":"Holtzman v. Beta Bionics, Inc., No. 26-cv-9999","stock_drop_jan_2026":"$11.85 per share decline (from $31.99 on Jan 8, 2026 to $20.14 on Jan 9, 2026)","largest_stock_drop_pct":"37%","lead_plaintiff_deadline":"November 3, 2026","stock_drop_feb_2026_pct":"4.9%","fda_form_483_unreported_complaints":"more than 18,000","new_patient_starts_miss_vs_estimates":"nearly 10%"}},"named_entities":{"people":[{"name":"Adam McCall","role":"attorney/contact at Bleichmar Fonti & Auld LLP"},{"name":"Holtzman","role":"named plaintiff in the class action (case caption)"}],"products":["iLet Bionic Pancreas insulin pump","iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action defendant / issuer (target)"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff securities law firm (release author)"},{"name":"Tesla, Inc.","relationship":"mentioned in law-firm marketing (past recovery)"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"mentioned in law-firm marketing (past recovery)"}],"dollarAmounts":[{"amount":"$11.85","context":"per-share stock decline January 8-9, 2026"},{"amount":"$31.99","context":"BBNX closing price January 8, 2026"},{"amount":"$20.14","context":"BBNX closing price January 9, 2026"},{"amount":"$0.66","context":"per-share stock decline February 24-25, 2026"},{"amount":"$13.55","context":"BBNX closing price February 24, 2026"},{"amount":"$12.89","context":"BBNX closing price February 25, 2026"},{"amount":"over $900 million","context":"BFA's past recovery from Tesla, Inc.'s Board of Directors (law-firm marketing)"},{"amount":"$420 million","context":"BFA's past recovery from Teva Pharmaceutical Ind. Ltd. (law-firm marketing)"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-19T10:19:06.890Z","global_importance":14,"audience_relevance":12,"importance_components":{"lawFirm":"Bleichmar Fonti & Auld LLP","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRisk":"FDA warning letter and device-safety allegations are material to BBNX but already public"}},"durationMs":53956,"modelName":"glm-5.3-flash"}}